Showing 5361-5370 of 5909 results for "".
- More Evidence Links Common Bladder Drug to Retinal Damagehttps://modernod.com/news/more-evidence-links-common-bladder-drug-to-retinal-damage/2477044/Pentosan polysulfate sodium (PPS), used widely for interstitial cystitis, may lead to retinal damage, according to a new study that adds weight to this previously suggested link, as reported by Reuters. Interstitial cystitis causes
- Adverum Biotechnologies Doses First Patient in Third Cohort of OPTIC Clinical Trial of Intravitreal Gene Therapy for Wet AMDhttps://modernod.com/news/adverum-biotechnologies-doses-first-patient-in-third-cohort-of-optic-phase-1-clinical-trial-of-advm-022-intravitreal-gene-therapy-for-wet-amd/2477039/Adverum Biotechnologies announced that the first patient was dosed in the third cohort (n=9) of the ongoing OPTIC phase 1 clinical trial for ADVM-022 for the treatment of neovascular age-related macular degeneration (AMD). Patients in this cohort are receiving a single intravitreal injection of g
- Oculus Teams Up With BHVI to Improve Myopia Managementhttps://modernod.com/news/oculus-teams-up-with-bhvi-to-improve-myopia-management/2477036/Oculus and BHVI (Brien Holden Vision Institute) have announced an agreement that will allow Oculus to incorporate BHVI’s algorithms for tracking and estimating refractive error into its Myopia Master ophthalmic instruments developed for the management of myopia.
- New Combined Data from the Phase 2 and Phase 3 Teprotumumab Clinical Trials to be Presented during the American Thyroid Association Annual Meetinghttps://modernod.com/news/new-combined-data-from-the-phase-2-and-phase-3-teprotumumab-clinical-trials-to-be-presented-during-the-american-thyroid-association-annual-meeting/2477038/New pooled data from the phase 2 and phase 3 clinical trials of teprotumumab, an investigational medicine being developed by Horizon Therapeutics, will be presented during an oral plenary presentation at the 89th Annual Meeting of the American Thyroid Association (ATA) in Chicago on Oc
- Julia A. Haller, MD, Elected to National Academy of Medicinehttps://modernod.com/news/julia-a-haller-md-elected-to-national-academy-of-medicine/2477033/Wills Eye Hospital announced its Ophthalmologist-in-Chief, Julia A. Haller, MD, has been elected to the National Academy of Medicine (NAM), considered one of the highest honors in the fields of health and medicine, recognizing individuals who have demonstrated outstanding professional achievement
- Bausch Health Licenses Clearside Biomedical’s Xipere, An Investigational Treatment For Macular Edema Associated With Uveitishttps://modernod.com/news/bausch-health-licenses-clearside-biomedicals-xipere-an-investigational-treatment-for-macular-edema-associated-with-uveitis/2477035/Bausch Health Companies announced that an affiliate of Bausch Health has acquired an exclusive license for the commercialization and development of Xipere (triamcinolone acetonide suprachoroidal injectable suspension) in the United States and
- New Hope for Patients With Vision Loss at SAVIR-Center for Vision Restorationhttps://modernod.com/news/new-hope-for-patients-with-vision-loss-at-savir-center-for-vision-restoration/2477031/Persistent psychological stress, which is widely recognized as a consequence of vision loss, is also a major contributor to its development and progression, according to a study published in the EPMA Journal, the official journal of the European Association for Predictive, Preventive, and
- Wolfgang Haigis—Scientist Known for His Formulae—Dies at 72https://modernod.com/news/wolfgang-haigis-scientist-known-for-his-formulae-dies-at-72/2477025/The German Society for Cataract and Refractive Surgery (DGII) has announced that Prof. Dr. Wolfgang Haigis, a physicist working at the University of Wurzburg, died on October 15 at the age of 72. Dr. Haigis was a pioneer and a driving force in the development and the refinement of biometry
- Aura Biosciences Announces Updated Phase 1b/2 Clinical Data for AU-011 Presented at AAOhttps://modernod.com/news/aura-biosciences-announces-updated-phase-1b-2-clinical-data-for-au-011-presented-at-aao/2477015/Aura Biosciences announced the presentation of updated clinical data from its ongoing phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, the company’s lead product candidate for the first line treatment of primary choroidal melanoma, at the American Academy of
- Sleep Apnea Linked to Blinding Eye Disease in People with Diabeteshttps://modernod.com/news/sleep-apnea-linked-to-blinding-eye-disease-in-people-with-diabetes/2477016/New research from Taiwan shows that severe sleep apnea is a risk factor for developing diabetic macular edema, a complication of diabetes